The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area DOI
Chung‐Feng Huang, Po‐Cheng Liang, Pei‐Chien Tsai

et al.

Journal of Gastroenterology and Hepatology, Journal Year: 2023, Volume and Issue: 39(1), P. 193 - 201

Published: Sept. 20, 2023

Abstract Background and Aim The prevalence of metabolic dysfunction‐associated fatty liver disease (MAFLD) its interplay with hepatitis B virus (HBV) C (HCV) in terms severity is elusive. Methods A mass surveillance program was conducted a viral endemic area. objective to identify MAFLD/non‐MAFLD subjects advanced disease. Results Two thousand two hundred forty‐two (41.7%) the 5378 were identified as having MAFLD, 375 (7.0%) had proportions anti‐HCV HBsAg seropositivity 19.3% 9.7%, respectively. fibrosis non‐viral (NBNC), HBV HCV infection 2.8%, 5.7% 23.4%, Subjects MAFLD significantly higher proportion (8.7% vs 5.7%, P < 0.001). Factors associated included age (odds ratio [OR]/95% confidence interval [CI]: 4.8/3.7–6.0, 0.001), male sex (OR/CI: 1.3/1.0–1.7, = 0.019), 5.9/4.6–7.5, MAFLD‐lean dysregulation (MS) 2.6/1.3–5.2, 0.005; compared non‐MAFLD group) MAFLD‐diabetes 1.5/1.1–2.1, 0.008; group). did not aggravate patients hepatitis. However, among NBNC subjects, factors MS group 9.1/2.4–34.6, 0.001; MAFLD‐DM 2.0/1.2–3.2, 0.004; Conclusions diabetes risk effect more significant community level.

Language: Английский

Safety of tenofovir alafenamide in the context of hyperlipidemia and cardiovascular diseases: a nationwide analysis DOI

Jae Young Kim,

Hyuk Soon Kim, Jeong‐Ju Yoo

et al.

Hepatology International, Journal Year: 2025, Volume and Issue: unknown

Published: March 8, 2025

Language: Английский

Citations

2
Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B DOI
Shang‐Chin Huang, Tung‐Hung Su, Tai‐Chung Tseng

et al.

Hepatology International, Journal Year: 2023, Volume and Issue: 17(5), P. 1139 - 1149

Published: May 29, 2023

Language: Английский

Citations

31
Metabolic Dysfunction-Associated Steatotic Liver Disease Facilitates Hepatitis B Surface Antigen Seroclearance and Seroconversion DOI
Shang‐Chin Huang, Tung‐Hung Su, Tai‐Chung Tseng

et al.

Clinical Gastroenterology and Hepatology, Journal Year: 2023, Volume and Issue: 22(3), P. 581 - 590.e6

Published: Oct. 21, 2023

Language: Английский

Citations

26
Chronic Viral Hepatitis B and C Outweigh MASLD in the Associated Risk of Cirrhosis and HCC DOI
Mei‐Hsuan Lee,

Yi-Ting Chen,

Yu-Han Huang

et al.

Clinical Gastroenterology and Hepatology, Journal Year: 2024, Volume and Issue: 22(6), P. 1275 - 1285.e2

Published: Feb. 15, 2024

Language: Английский

Citations

13
Hepatitis B virus infection and metabolic dysfunction associated steatotic liver disease: Rising pandemic with complex interaction DOI Open Access

Ammara A Majeed,

Amna Subhan Butt

World Journal of Hepatology, Journal Year: 2025, Volume and Issue: 17(1)

Published: Jan. 6, 2025

Due to sedentary lifestyle and rising prevalence of obesity, patients with general population those who are infected chronic hepatitis B found have metabolic dysfunction associated steatotic liver disease (MASLD). Both virus (HBV) infection MASLD can damage hepatocytes in their own way, but concomitant HBV-MASLD has its clinical implications. Cherry on top is the presence diabetes mellitus, hypertension or obesity which added more chances unfavorable outcomes these patients. In this article, we comment article by Wang et al published recent issue. This provides a comprehensive overview complex interaction between HBV-MASLD, HBV alone We discuss key findings from studies, including promising observed concurrent MASLD, warrants further research. The insights presented here offer renewed understanding interaction.

Language: Английский

Citations

1
Inflammatory Indices and MAFLD Prevalence in Hypertensive Patients: A Large-Scale Cross-Sectional Analysis from China DOI Creative Commons
Di Shen, Xintian Cai,

Junli Hu

et al.

Journal of Inflammation Research, Journal Year: 2025, Volume and Issue: Volume 18, P. 1623 - 1638

Published: Feb. 1, 2025

Objective: Hypertension development and progression are largely influenced by inflammation, which plays a critical role activating the immune system causing damage to vascular endothelium. Metabolic dysfunction-associated fatty liver disease (MAFLD) is also associated with chronic low-grade drives via metabolic imbalances adipose tissue dysfunction. This study investigates relationship between inflammatory indices MAFLD in hypertensive patients assesses predictive accuracy of these for MAFLD. Methods: We performed cross-sectional analysis involving 34,303 from Chinese hospital-based registry. The diagnosis was established using dysfunction criteria alongside evidence hepatic steatosis confirmed through imaging. Complete blood counts were used calculate indices, including monocyte-to-lymphocyte ratio (MLR), neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR), systemic response index (SIRI), immune-inflammation (SII), aggregate inflammation (AISI). To assess MAFLD, multivariable logistic regression adjustments potential confounders. diagnostic performance analyzed receiver operating characteristic (ROC) curves area under curve (AUC) calculations. Results: Patients exhibited significantly elevated levels all compared those without. After adjustment, each standard deviation increase AISI, SIRI, SII 74%, 62%, 58% increased odds respectively. AUC AISI 0.659, indicating moderate accuracy. AUCs SIRI 0.626 0.619, respectively, while NLR, PLR, MLR had lower 0.593, 0.558, 0.589, Conclusion: In patients, especially show strong association their utility risk stratification within clinical settings. Further research needed evaluate effectiveness markers management Keywords: metabolic-dysfunction-associated disease, hypertension,

Language: Английский

Citations

1
All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease DOI
Shang‐Chin Huang, Tung‐Hung Su, Tai‐Chung Tseng

et al.

Journal of Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 1, 2024

Language: Английский

Citations

7
Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients DOI
Mi Na Kim, Kyungdo Han, Juhwan Yoo

et al.

International Journal of Cancer, Journal Year: 2023, Volume and Issue: 153(8), P. 1448 - 1458

Published: July 13, 2023

Metabolic dysfunction-associated fatty liver disease (MAFLD) can coexist with chronic viral hepatitis. MAFLD is a heterogeneous because the diagnostic criteria include various metabolic traits. We aimed to identify patients at high risk of poor long-term outcomes based on subgroups in hepatitis patients. evaluated 63 273 B and C Patient index ≥30 was defined have hepatic steatosis. as presence steatosis any one following three conditions, overweight/obesity, type 2 diabetes or ≥2 factors. The prevalence 38.4% (n = 24 290). During median 8.8-year follow-up, 1839 HCCs 2258 deaths were documented Among patients, could HCC mortality, whereas overweight/obesity factors did not. Compared non-MAFLD mortality significantly higher diabetic (adjusted hazard ratio [aHR] 1.34, 95% confidence interval [CI] 1.26-1.43 for HCC; aHR 1.15, CI 1.08-1.22 mortality). Risk (aHR 1.40, 1.26-1.55 1.77, 1.63-1.93 mortality) compared non-diabetic Diabetic associated increased among Our findings highlight need close surveillance effective treatment these high-risk reduce

Language: Английский

Citations

16
Low liver fat in non‐alcoholic steatohepatitis‐related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality DOI Open Access
Sung Won Lee, Daniel Q. Huang, Ricki Bettencourt

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2023, Volume and Issue: 59(1), P. 80 - 88

Published: Nov. 15, 2023

Progression to cirrhosis in non-alcoholic steatohepatitis (NASH) is associated with a decrease liver fat. However, the prognostic significance of fat content NASH-related significant fibrosis and unclear.

Language: Английский

Citations

16
The overlap with metabolic dysfunction‐associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis DOI Creative Commons
María Hernández‐Pérez,

Daniel Riado,

E García de la Peña

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: 60(5), P. 613 - 619

Published: June 25, 2024

Summary Background and Aims The relationship between primary biliary cholangitis (PBC) metabolic dysfunction‐associated steatotic liver disease, its impact on treatment response prognosis, remains underexplored. Methods Patient cohort from two centres comprising long‐term follow‐up data. All patients had histologically confirmed PBC. Biopsies were classified according to Non‐Alcoholic Steatohepatitis Clinical Research Network. Diagnosis of disease was established when steatosis exceeded 5%, along with at least one risk factor. Patients specific aetiologies steatosis, other diseases, incomplete results inadequate ursodeoxycholic acid excluded. Data initiating second‐line censored. Treatment assessed using the Toronto, Paris II AST‐to‐platelet 12‐month criteria. UK PBC Globe scores, events utilized as outcome measures. Results study included 129 patients, 36 showing overlap steatosis. showed worse prognosis (61.1% vs. 33.3%, p = 0.004), Toronto (52.5% 24.7%, 0.002), >0.54 (36.1% 17.2%, 0.021), >0.30 (49.2% 29.2%, 0.033) 5, 10 15 years ( ≤ 0.001). Liver‐related mortality transplant more prevalent in group In multivariate analysis, dyslipidaemia advanced fibrosis independently associated outcomes. Conclusions Our findings suggest that worsens

Language: Английский

Citations

5